

University of Groningen

Angiogenic growth factors and their receptors in first-trimester human decidua of pregnancies further complicated by preeclampsia or fetal growth restriction

Plaisier, M.; Streefland, E.; Koolwijk, P.; van Hinsbergh, V. W. M.; Helmerhorst, F. M.; Erwich, J. J. H. M.

Published in:
Reproductive Sciences

DOI:
[10.1177/1933719108317300](https://doi.org/10.1177/1933719108317300)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2008

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Plaisier, M., Streefland, E., Koolwijk, P., van Hinsbergh, V. W. M., Helmerhorst, F. M., & Erwich, J. J. H. M. (2008). Angiogenic growth factors and their receptors in first-trimester human decidua of pregnancies further complicated by preeclampsia or fetal growth restriction. *Reproductive Sciences*, 15(7), 720-726. <https://doi.org/10.1177/1933719108317300>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Reproductive Sciences

<http://rsx.sagepub.com>

Angiogenic Growth Factors and Their Receptors in First-Trimester Human Decidua of Pregnancies Further Complicated By Preeclampsia or Fetal Growth Restriction

M. Plaisier, E. Streefland, P. Koolwijk, V.W.M. van Hinsbergh, F.M. Helmerhorst and J.J.H.M. Erwich

Reproductive Sciences 2008; 15; 720 originally published online Jun 18, 2008;

DOI: 10.1177/1933719108317300

The online version of this article can be found at:

<http://rsx.sagepub.com/cgi/content/abstract/15/7/720>

Published by:



<http://www.sagepublications.com>

On behalf of:



[Society for Gynecologic Investigation](#)

Additional services and information for *Reproductive Sciences* can be found at:

Email Alerts: <http://rsx.sagepub.com/cgi/alerts>

Subscriptions: <http://rsx.sagepub.com/subscriptions>

Reprints: <http://www.sagepub.com/journalsReprints.nav>

Permissions: <http://www.sagepub.com/journalsPermissions.nav>

Citations <http://rsx.sagepub.com/cgi/content/refs/15/7/720>

Angiogenic Growth Factors and Their Receptors in First-Trimester Human Decidua of Pregnancies Further Complicated By Preeclampsia or Fetal Growth Restriction

M. Plaisier, MD, E. Streefland, MD, P. Koolwijk, PhD,
V.W. M. van Hinsbergh, PhD, F. M. Helmerhorst, MD, and J. J. H. M. Erwich MD, PhD

Disturbances in decidual and placental vascular development may play a role in the pathogenesis of pregnancy complications. This study focused on the role of angiogenic factors in the first trimester in the pathogenesis of preeclampsia (PE) and/or fetal growth restriction (FGR). First-trimester decidua was obtained during chorionic villous sampling. The expression of the angiogenic factors was determined by reverse transcriptase polymerase chain reaction and related to the pregnancy outcome. First-trimester decidua expressed all angiogenic factors. The differential expression of angiogenic factors appeared to be more prominent in FGR than in PE. These first-trimester samples provided a unique opportunity to obtain information regarding the onset of PE and FGR. First-trimester changes in angiogenic factor expression may well occur as a compensatory mechanism. This, in turn, may unintentionally set the stage for increased angiogenesis and altered decidual/placental vascular adaptation, which may be part of the pathogenesis of PE and/or FGR.

KEY WORDS: Angiogenic factors, first trimester, decidua, preeclampsia, fetal growth restriction.

Disturbances in decidual and placental vascular development may play a role in complications of pregnancy, like preeclampsia (PE) and fetal growth restriction (FGR).¹⁻³ Preeclampsia affects 5% to 10% of pregnancies and is responsible for substantial maternal and neonatal morbidity and mortality. Predominant features are maternal systemic vascular endothelial dysfunction and microangiopathy. Target organs are the brain (seizures or eclampsia), liver (hemolysis, elevated liver enzymes, low platelets [HELLP] syndrome), kidney

(proteinuria), and the uteroplacental unit (fetal distress and growth restriction). Failure of placental vascular development has been linked to the pathogenesis of PE and FGR.^{4,5}

Decidual vascular adaptation to pregnancy is characterized by high levels of both angiogenesis, the formation of new vessels from existing vasculature, and vasculogenesis, blood vessel generation from angioblast precursor cells.^{6,7} Additionally, vascular mimicry or pseudovasculogenesis is also taking place where cytotrophoblasts convert to an endothelial phenotype. Failure of angiogenesis and pseudovasculogenesis has been proposed as processes in the inception of PE and FGR.⁸

Numerous factors are thought to play a role in normal vascular adaptation to implantation.⁹ Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are probably the best-studied factors.¹⁰⁻¹² VEGF interacts with VEGFR-1 (Flt-1) and VEGFR-2 (KDR) to promote endothelial cell proliferation, cell migration, and vascular permeability. In rabbits, VEGF, together with its receptor Flt-1, plays an active role in the angiogenic process during implantation.¹⁰

From the Department of Gynecology and Reproductive Medicine, Leiden University Medical Center, Leiden, the Netherlands (MP, FMH); Department of Biomedical Research, TNO-QoL, Leiden, the Netherlands (MP); Department of Obstetrics and Gynecology, University Medical Center Groningen, Groningen, the Netherlands (ES, JJHME); and Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, the Netherlands (PK, VWMvH).

Address correspondence to: M. Plaisier, MD, Section of Reproduction Medicine, Department of Gynecology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands. E-mail: m.plaisier@lumc.nl.

Reproductive Sciences Vol. 15 No. 7 September 2008 720-726
DOI: 10.1177/1933719108317300

© 2008 by the Society for Gynecologic Investigation

PlGF shares biochemical and functional features with VEGF and interacts with VEGFR-1 (Flt-1). PlGF and VEGF-A have synergistic effects regarding angiogenesis, but vessels induced by PlGF are more mature and stable than vessels induced by VEGF-A.^{13,14} PlGF is abundantly expressed in the human placenta. Both VEGF-A and PlGF may be important paracrine regulators of decidual angiogenesis and autocrine mediators of trophoblast function.^{11,15} The soluble variant of Flt-1 has been associated with the pathogenesis of PE.^{4,5}

A second family of growth factors, the angiopoietins, is also known for their regulating capacities regarding angiogenesis.¹⁶ Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) bind with equal affinity to their receptor TIE-2, but have different functions. Ang-1 maintains vessel integrity and plays a role in the later stages of vascular remodeling.¹⁶ Ang-2 is a functional antagonist of Ang-1 and leads to loosening of cell-cell interactions and allows access to angiogenic inducers like VEGF.¹⁷ Coexpression of VEGF and Ang-2 induces angiogenesis, but Ang-2 results in vascular regression in the absence of angiogenic signals.¹⁸ Ang-1 and Ang-2 have both been detected in decidual and placental tissues.^{11,17}

Various decidual cell types are capable of producing angiogenic factors. We recently showed the production of PlGF, KDR, Flt-1, Ang-2, and TIE-2 by endothelial cells and extravillous trophoblasts. Decidual stromal cells, glandular epithelium, and perivascular smooth muscle cells were found to produce all studied angiogenic factors.¹¹ Uterine natural killer cells are also abundantly present in first-trimester decidua and are known to produce PlGF, VEGF, Ang-1, and Ang-2.¹⁹

The possible correlation of PE and FGR with impaired vascular development has been studied in placental tissues mainly after the onset of disease.^{9,20,21} However, whether decidual vascularization is also related to the pathogenesis of both diseases is not known. Information regarding the expression of angiogenic factors in first-trimester tissues would be helpful in understanding PE and FGR. The present study focused on the role of first-trimester angiogenic growth factors in the pathogenesis of PE and/or FGR. The expressions of VEGF-A, PlGF, Flt-1, KDR, Ang-1, Ang-2, and TIE-2 were determined in first-trimester decidua obtained during routine chorion villous sampling (CVS). The included patients were followed throughout their pregnancy to be able to relate the angiogenic factor expression to the pregnancy outcome, that is, uncomplicated, PE, or FGR.

MATERIALS AND METHODS

Study Group and Tissue Collection

Decidual samples were obtained from viable first-trimester pregnancies during routine CVS. Chorion villous sampling was performed vaginally between 10 and 12 weeks of gestation. Main indications were maternal age and serum screening related risk for aneuploidy. Gestational age was calculated according to the last menstrual period and confirmed by ultrasound (crown rump length). After CVS, surplus decidual tissue was microscopically separated from the chorion villi and immediately stored at -20°C until RNA isolation. One sample per person was collected with an average size of 5 mg to 15 mg.

Follow-up of the pregnancies was available through a postpartum questionnaire. Patients experiencing FGR ($n = 10$) and PE/HELLP ($n = 9$) were selected. Preeclampsia was defined as diastolic blood pressure (BP) of minimal 90 mm Hg, or a raise of 15 mm Hg compared with first-trimester BP, combined with proteinuria of at least 300 mg/day. For FGR, criteria according to Kloosterman²² were used. Birth weight was corrected for gestational age and FGR was defined as a corrected birth weight below the 5th percentile. All cases were matched to controls based on gestational age, maternal age, and parity at time of CVS ($N = 19$). Patients with concurrent morbidity (eg, diabetes) or medication were excluded. Fetal karyotyping showed no chromosomal abnormalities. Weight and the number of smokers were comparable between cases and controls. Patients were informed that surplus material was used for research, according to the "Guideline for Good Use" by the Federation of Medical Scientific Associations and informed consent was provided by all study subjects. Patient characteristics are described in Table 1.

RNA Isolation and cDNA Synthesis

Tissue samples were incubated in 1.5 mL RNA Later Ice (Ambion, Austin, Texas) for 48 hours at -20°C . After centrifugation, the tissue samples were lysed in lysis buffer (RLT buffer [Qiagen] and β -mercapto-ethanol) using plastic mortars and RNA isolation was performed using RNeasy columns (Qiagen Benelux BV, Venlo, the Netherlands) following recommended protocol. mRNA was dissolved in RNase-free water. mRNA quantity and quality was determined by measuring its absorbance in a spectrophotometer (NanoDrop ND-1000, NanoDrop

Table 1. Characteristics of the FGR and PE Study Groups and Matched Control Groups^a

	FGR (n = 10)	Control (n = 10)	PE/HELLP (n = 9)	Control (n = 9)
At CVS				
Age (years)	39.5 ± 2.1	39.6 ± 2.1	39.2 ± 1.9	39.2 ± 1.9
GA (days)	75.6 ± 3.2	76.5 ± 2.5	78.6 ± 3.9	77.3 ± 4.4
Parity	1.5 ± 1.4	1.1 ± 0.6	0.7 ± 0.9	0.7 ± 0.9
At delivery				
GA (days)	278 ± 11	282 ± 12	261 ± 22	271 ± 10
Birth weight (g)	2477 ± 286 ^b	3648 ± 475	2648 ± 798	3420 ± 382

Abbreviations: FGR, fetal growth restriction; PE, preeclampsia; HELLP, hemolysis, elevated liver enzymes, low platelets; CVS, chorion villous sampling; GA, gestational age.

^aData are presented as mean ± standard deviation (mean ± SD).

^b*P* < .05 versus control group.

Technologies, Wilmington, Delaware) and reverse transcription was performed with 1 µg total RNA, random primers, and a cDNA synthesis kit (Ready-to-go You-Prime first strand beads, Amersham Biosciences, Buckinghamshire, United Kingdom). The 32 µL of cDNA obtained was diluted 1:3.

Real-Time Reverse Transcriptase Polymerase Chain Reaction

mRNA expression was quantified according to the Taqman real-time polymerase chain reaction (PCR) method using validated primer and probe (FAM/TAMRA double-labeled) sets for VEGF-A, Flt-1, KDR, PlGF, Ang-1, Ang-2, and TIE-2. Glycerlyaldehyde-3-phosphate dehydrogenase (GAPDH, primers/VIC-labeled probe) was used as an endogenous reference gene (all purchased from Applied Biosystems, Foster City, California). β-Actin, β₂-microglobulin, and cyclophilin were also used as reference genes and showed similar results (data not shown).

RT-PCR for target gene/GAPDH pairs was performed in 12.5-µL reactions, containing 2.5 µL cDNA solution, using Mastermix (RT-QP2X-03, Eurogentec, Maastricht, the Netherlands), DNase-free water, and the primer/probe sets described above. Reactions were performed in duplicate and mRNA levels were expressed in cycle threshold (Ct). To correct for the RNA input, the difference in Ct values of target and reference genes (dCt = Ct(target gene) – Ct(GAPDH)) was calculated. The difference between cases and controls (ddCt) was calculated as ddCt = dCt(case) – dCt(control) and the fold induction was calculated as 2^{-ddCt}. In addition, Ct values were quantified into nanograms per microliter (ng/µL) using a standard curve of total RNA. Cases and controls were

compared by the ratio ng/µL(case)/ng/µL(control). Water and negative-RT samples, obtained by the omission of the reverse transcriptase enzyme in the cDNA reaction, were used as negative controls.

Statistics

The mRNA expression levels were compared between cases and matched controls. A general linear model for repeated measurements, analysis of variance, was performed to analyze the paired data between matched cases and controls (SPSS 11.5). *P* values <.05 were considered significant.

RESULTS

The expression of the angiopoietins and their receptor TIE-2 and of VEGF, PlGF and their receptors KDR and Flt-1 were evaluated. The mRNA levels in all cases were calculated and expressed as ddCt, ng/µL and as fold induction compared with the control group (Tables 2 and 3). All factors were present at mRNA level in decidua of cases as well as controls.

Control Group

The control patients were matched to the cases; 10 controls to FGR patients and 9 controls to PE patients. First, mRNA expression was analyzed in all the control patients. In these controls, PlGF showed the most abundant expression with a mean of 4.6 ± 1.8 ng/µL. KDR, Flt-1, and Ang-2 showed a moderate expression with means of 0.4 ± 0.1, 0.5 ± 0.1, and 0.8 ± 0.3 ng/µL, respectively. VEGF-A, Ang-1, and TIE-2 were only dimly

Table 2. First-Trimester Decidual mRNA Expression of Angiogenic Factors (in Cycle Threshold, Ct)^{a,b}

Angiogenic Factor	mRNA Content (dCt) ^c		Fold Induction ^d	
	FGR (n = 10)	PE (n = 9)	FGR (n = 10)	PE (n = 9)
VEGF-A	-1.5 ± 1.2	-0.5 ± 0.8	83 ± 70	3 ± 1
PlGF	0.5 ± 1.6	-2.0 ± 1.4	31 ± 21	51 ± 34
KDR	-0.5 ± 1.8	-1.8 ± 1.1	32 ± 25	17 ± 9
Flt-1	0.4 ± 0.6	-1.1 ± 0.7	2 ± 0.9	8 ± 6
Ang-1	-1.5 ± 1.9	-1.7 ± 1.6	84 ± 50	68 ± 40
Ang-2	-0.4 ± 1.3	0.1 ± 1.3	11 ± 5	6 ± 5
TIE-2	-1.2 ± 1.5	-3.1 ± 1.3	34 ± 25	110 ± 83

Abbreviations: FGR, fetal growth restriction; PE, preeclampsia.

^aFirst-trimester decidual mRNA expression was determined by reverse transcriptase polymerase chain reaction and compared between pregnancies resulting in FGR or PE and their matched controls. The “repeated measures analysis of variance” was performed to analyze the data.

^bData are expressed as mean ± standard error of the mean (mean ± SEM).

^cmRNA content was expressed in cycle threshold (Ct). Mean Ct per gene: GAPDH, 25; VEGF-A, 26.0; PlGF, 29.2; KDR, 28.5; Flt-1, 28.4; Ang-1, 33; Ang-2, 27.4; and TIE-2, 32.1. The Ct values were corrected for the mRNA input by calculating the difference in Ct of target and reference genes: dCt = Ct(target gene) – Ct(GAPDH).

^dThe difference between cases and controls (ddCt) was calculated as ddCt = dCt(case) – dCt(control). Fold induction in cases compared with controls was calculated as 2^{-ddCt}.

expressed with means of 0.04 ± 0.001, 0.01 ± 0.00, and 0.15 ± 0.06 ng/μL, respectively (data not shown).

Fetal Growth Restriction Group

The FGR group showed no significant differential expression compared with the control group. Strikingly, the expression of VEGF-A (83-fold), PlGF (31-fold), KDR (32-fold), Ang-1 (84-fold), Ang-2 (11-fold), and TIE-2 (34-fold) appeared unregulated in cases compared with controls. However, significance was not reached due to the large interindividual variation. Flt-1 showed comparable expression levels in cases and controls. The same pattern was found with regard to calculated ng/μL (Tables 2 and 3).

Preeclampsia Group

The PE group showed no significant differential expression compared with the control group. PlGF (51-fold), Ang-1 (68-fold), and TIE-2 (110-fold) appeared unregulated in cases compared with controls. However, these differences were not significant due to the large interindividual variation. VEGF-A, KDR, Flt-1, and Ang-2 showed comparable expression levels in cases and controls. With regard to calculated ng/μL, the same pattern was found (Tables 2 and 3).

DISCUSSION

The results showed that first-trimester decidual tissues obtained from CVS expressed all examined angiogenic factors. mRNA levels of VEGF-A, PlGF, KDR, Ang-1, Ang-2, and TIE-2 appeared unregulated in FGR cases compared with matched controls. In addition, PlGF, Ang-1, and TIE-2 mRNA appeared unregulated in PE cases compared with matched controls. However, the large interindividual variation disallowed an unequivocal conclusion. The differential expression of angiogenic factors appeared more prominent in FGR than in PE.

The origin of both PE and FGR probably starts in the first-trimester, before the onset of overt disease during the last trimester. Our first-trimester decidual samples provide a unique opportunity to obtain information regarding the onset of PE and FGR. The fact that the decidual samples were obtained together with villous tissue offers valid information on the original localization in utero, namely underneath the implantation site. Shortcomings are also present. No histological investigation could be performed on the number of trophoblasts and other cell types because of the small amounts of material in each sample. Also, the study groups are small because of the rarity of the samples. This results in rather high standard deviations, which makes interpretation of the data difficult. However, the 10-fold to 100-fold induction

Table 3. First-Trimester Decidual mRNA Expression of Angiogenic Factors^{a,b}

Angiogenic Factor	mRNA Content (ng/ μ L) ^c		Fold induction ^d	
	FGR (n = 10)	PE (n = 9)	FGR (n = 10)	PE (n = 9)
VEGF-A	0.1 \pm 0.0	0.1 \pm 0.0	53 \pm 46	2 \pm 1
PlGF	4.1 \pm 1.8	8.2 \pm 3.1	33 \pm 21	35 \pm 24
KDR	0.7 \pm 0.3	1.7 \pm 0.8	26 \pm 17	13 \pm 8
Flt-1	0.6 \pm 0.2	2.0 \pm 1.3	2 \pm 1	3 \pm 2
Ang-1	0.02 \pm 0.0	0.4 \pm 0.4	59 \pm 34	29 \pm 21
Ang-2	0.4 \pm 0.2	3.6 \pm 2.0	8 \pm 4	5 \pm 3
TIE-2	0.9 \pm 0.8	19.6 \pm 19.5	37 \pm 30	68 \pm 47

Abbreviations: FGR, fetal growth restriction; PE, preeclampsia.

^aFirst-trimester decidual mRNA expression was determined by reverse transcriptase polymerase chain reaction and compared between pregnancies resulting in FGR or PE and their matched controls. The “repeated measures analysis of variance” was performed to analyze the data.

^bData are expressed as mean \pm standard error of the mean.

^cmRNA content was expressed in cycle threshold (Ct). Mean Ct per gene: GAPDH, 25; VEGF-A, 26.0; PlGF, 29.2; KDR, 28.5; Flt-1, 28.4; Ang-1, 33; Ang-2, 27.4; and TIE-2, 32.1. Cycle threshold were converted into ng/ μ L using a standard curve of total RNA. Values were corrected for mRNA input by calculating the ratio [(ng/ μ L(target gene))/(ng/ μ L(GAPDH))] and these values are expressed as “mRNA content” in the table.

^dFold induction in cases compared with controls was calculated as the ratio ng/ μ L(case)/ng/ μ L(controls).

of genes in these small groups promises significant differences when groups could be expanded.

Current knowledge regarding PE suggests that defective vascular remodeling of maternal spiral arteries leads to impaired invasion of trophoblasts, placental insufficiency, and ischemia.⁴ The affected placenta releases soluble anti-angiogenic factors, like soluble Flt-1 (sFlt-1) and endoglin (sEng).^{5,23,24} These factors alter the angiogenic balance, mainly by neutralizing VEGF and PlGF. Furthermore, these factors are able to induce systemic endothelial dysfunction and finally induce clinical PE.^{5,25-27} The serum and placental levels of these factors have been studied extensively in term pregnancies, without reaching complete consensus with regard to VEGF. Several reports have described increased, comparable, and even decreased VEGF levels in placenta of term PE pregnancies.^{9,12,28,29} PlGF was decreased in serum of PE in the third trimester.^{20,30} Term placental tissue showed reduced Ang-2 mRNA and equal Ang-1 mRNA in PE.³¹ No reports on these angiogenic factors are available regarding first-trimester tissues.

In the present study, mRNA levels of PlGF, Ang-1, and TIE-2 appeared upregulated in future PE patients compared with controls. VEGF-A, KDR, Flt-1, and Ang-2 showed comparable expression levels. No previous reports were found to reference these data in first-trimester tissues. Only first-trimester serum data are available, showing reduced PlGF and increased VEGF and sFlt-1 in first-trimester serum of PE patients.^{32,33}

The studied Flt-1 represents both the soluble and membrane bound Flt-1 and unfortunately no differentiation can be made between both types. The comparable overall Flt-1 expression in PE cases probably corresponds to the described decline of membrane bound Flt-1 and the known increase of soluble Flt-1.³⁴

Fetal growth restriction has been proposed to be induced by relatively high oxygen levels, which cause a disturbed expression of angiogenic factors and altered angiogenesis in placental villi.³⁵⁻³⁷ These relative hyperoxic conditions may cause the decreased VEGF and increased PlGF expression in FGR placentas because these factors are inversely regulated by oxygen.^{38,39} An ovine model for FGR demonstrated increased Ang-1, Ang-2, and TIE-2 levels in early gestation before FGR was clinically detected. Later in gestation, decreased TIE2 expression was associated with FGR.⁴⁰ Whether decidual angiogenesis is also affected by the altered oxygen levels in FGR is still not demonstrated but plausible.

The present study showed that the mRNA levels of angiogenic factors in first-trimester decidua were altered in the FGR group compared to the control group, although differences were not significant. The expression of VEGF-A, PlGF, KDR, Ang-1, Ang-2, and TIE-2 appeared upregulated in FGR cases and Flt-1 showed comparable expression levels in cases and controls.

The relative hyperoxia in FGR and the oxygen effect on angiogenic factors are mainly described in fetoplacental tissues and trophoblasts. If the theory is valid for

first-trimester decidua, one would expect decreased VEGF and Ang-2 and increased Ang-1 and PlGF mRNA levels in FGR patients.^{31,37,39,41} However, mRNA levels of all 4 genes appeared increased in FGR compared with matched controls. This might be explained by a different expression and regulation of angiogenic factors in first-trimester tissues compared with third-trimester tissues. For example, VEGF-A and Ang-1 were shown to increase and Ang-2 was shown to decrease as gestation progresses.⁹ In contrast, other studies have demonstrated a decline in VEGF-A mRNA as gestation progresses.⁴² In addition, oxygen influences in decidua may differ from its influences in villous tissue and/or trophoblasts. No references were found regarding oxygen regulation in decidua. Finally, histological differences or differences in the number of trophoblasts between the studied specimens cannot be ruled out.

The differential expression of angiogenic factors appeared more prominent in FGR than in PE and therefore a more pronounced disbalance between angiogenic factors might be involved in the pathogenesis of FGR. Overall, enhanced angiogenic factors in both patient groups might represent an (ineffective) vascular rescue mechanism in response to unidentified situation(s) and/or event(s). This compensatory mechanism may, in turn, unintentionally induce increased nonbranching angiogenesis, altered decidual and placental vascular adaptation, and functional placental insufficiency, all of which may result in PE and/or FGR during late gestation.

REFERENCES

- Ahmed A, Perkins J. Angiogenesis and intrauterine growth retardation. *Baillieres Best Pract Res Clin Obstet Gynaecol.* 2000; 14:981-998.
- Ong S, Lash G, Baker PN. Angiogenesis and placental growth in normal and compromised pregnancies. *Baillieres Best Pract Res Clin Obstet Gynaecol.* 2000;14:969-980.
- Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. *Am J Reprod Immunol.* 2004;51:257-268.
- Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? *J Clin Invest.* 2003;111:600-602.
- Maynard SE, Min J, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sflt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest.* 2003;111:649-658.
- Burton GJ, Jauniaux E, Watson AL. Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd collection revisited. *Am J Obstet Gynecol.* 1999;181:718-724.
- Pijnenborg R, Bland JM, Robertson WB, Brosens I. Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. *Placenta.* 1983;4:397-413.
- Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. *Am J Pathol.* 2002;160:1405-1423.
- Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB. Human placental vascular development: vasculogenic and angiogenic transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1 and angiopoietin-2. *J Clin Endocrinol Metab.* 2002;87:4213-4224.
- Das SK, Chakraborty I, Wang J, Dey SK, Hoffman LH. Expression of vascular endothelial growth factor (VEGF) and VEGF-receptor messenger ribonucleic acids in the peri-implantation rabbit uterus. *Biol Reprod.* 1997;56: 1390-1399.
- Plaisier M, Rodrigues S, Willems F, et al. Different degree of vascularisation and its relation to the expression of VEGF, PlGF, angiopoietins and their receptors in 1st trimester decidua. *Fertil Steril.* 2007;88:176-187.
- Chung J, Song Y, Wang Y, Magness RR, Zheng J. Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. *J Clin Endocrinol Metab.* 2004;89:2484-2490.
- Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat Med.* 2001;7:575-583.
- Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. *Nat Med.* 2002;8:831-840.
- Sherer DM, Abulafia O. Angiogenesis during implantation, and placental and early embryonic development. *Placenta.* 2001;22:1-13.
- Geva E, Jaffe RB. Role of angiopoietins in reproductive tract angiogenesis. *Obstet Gynecol Surv.* 2000;55:511-519.
- Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. *Science.* 1997;277:55-60.
- Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. *Circ Res.* 1998;83:233-240.
- Li XF, Charnock-Jones DS, Zhang E, Hiby S, Malik S, Day K. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. *J Clin Endocrinol Metab.* 2001; 86:1823-1834.

20. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. *Lancet*. 2001;357:53-56.
21. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of PlGF: evidence for abnormal placental angiogenesis in pathologic pregnancies. *Am J Obstet Gynecol*. 2003;188:177-182.
22. Kloosterman GJ. Over intra-uteriene groei en de intra-uteriene groeicurve. [Intrauterine growth and intrauterine growth curves]. *Ned Tijdschr Verloskd Gynaecol*. 1969;69:349-365.
23. Clark DE, Smith SK, He Y, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. *Biol Reprod*. 1998;59:1540-1548.
24. Tjoa ML, Levine RJ, Karumanchi SA. Angiogenic factors in preeclampsia. *Front Biosci*. 2007;112:2395-2402.
25. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in pre-eclampsia. *Circ Res*. 2004;95:884-891.
26. Hayman R, Brockelsby J, Kenny L, Baker P. Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. *J Soc Gynecol Investig*. 1999;6:3-10.
27. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. *J Biol Chem*. 2003;278:12605-12608.
28. Ranheim T, Staff AC, Henriksen T. VEGF mRNA is unaltered in decidua and placental tissues in preeclampsia at delivery. *Acta Obstet Gynecol Scand*. 2001;80:93-98.
29. Sgambati E, Marini M, Zappoli, et al. VEGF expression in the placenta from pregnancies complicated by hypertensive disorders. *BJOG*. 2004;111:564-570.
30. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. *Hypertension*. 2005;46:1077-1085.
31. Zhang EG, Smith SK, Baker PN, Charnock-Jones DS. The regulation and localization of angiopoietin-1, -2, and their receptor Tie2 in normal and pathologic human placentae. *Mol Med*. 2001;7:624-635.
32. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med*. 2004;350:672-683.
33. Bosio PM, Wheeler T, Anthony F, Conroy R, O'Herlihy C, McKenna P. Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. *Am J Obstet Gynecol*. 2001;184:146-152.
34. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathological consequences. *J Clin Endocrinol Metab*. 2003;88:5555-5563.
35. Burton GJ. On 'oxygen and placental villous development: origins of fetal hypoxia'. *Placenta*. 1997;18:625-626.
36. Kingdom JCP, Kaufmann P. Oxygen and placental villous development: origins of fetal hypoxia. *Placenta*. 1997;18:613-621.
37. Regnault TRH, de Vrijer B, Galan HL, et al. The relationship between transplacental O₂ diffusion and placental expression of PlGF, VEGF, and their receptors in a placental insufficiency model of fetal growth restriction. *J Physiol*. 2003;550:641-656.
38. Lyall F. Placental expression of VEGF in placentae of preeclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. *Placenta*. 1997;18:269-276.
39. Khaliq A, Dunk C, Jiang J, et al. Hypoxia downregulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. *Lab Invest*. 1999;79:151-170.
40. Erickson Hagen AS, Orbus RJ, Wilkening RB, Regnault TRH, Anthony RV. Placental expression of angiopoietin-1, angiopoietin-2 and Tie-2 during placental development in an ovine model of placental insufficiency—fetal growth restriction. *Pediatr Res*. 2005;58:1228-1232.
41. Sharkey AM, Day K, McPherson A, et al. Vascular endothelial growth factor expression in humane endometrium is regulated by hypoxia. *J Clin Endocrinol Metab*. 2000;85:402-409.
42. Cooper JC, Sharkey AM, Charnock-Jones D, Palmer CR, Smith SK. VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. *BJOG*. 1996;103:1191-1196.